X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to evaluate ZW25 (zanidatamab), Jazz's investigational HER2-targeted bispecific antibody that can simultaneously bind two non-overlapping epitopes of HER2, known as biparatopic binding, in multiple HER2-expressing cancers.
Lead Product(s): Zanidatamab
Therapeutic Area: Oncology Product Name: ZW25
Highest Development Status: Phase IIProduct Type: Large molecule
Recipient: Jazz Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 07, 2023
Details:
Mino-Lok (MLT), a novel antibiotic lock therapy that combines minocycline with edetate disodium, which is investigated for the treatment of patients with catheter-related blood stream infections.
Lead Product(s): Minocycline Hydrochloride,Edetate Calcium Disodium,Ethanol
Therapeutic Area: Infections and Infectious Diseases Product Name: Mino-Lok
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Citius Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2023
Details:
NY-ESO-1 TCR/IL-15 NKs are adoptive Natural Killer (NK) cells expressing an affinity-enhanced T-cell receptor (TCR) reactive directed against the NY-ESO-1-specific cord blood-derived NK cells.
Lead Product(s): NY-ESO-1 TCR/IL-15 NK Cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Recipient: Replay Bio
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 24, 2023
Details:
NY-ESO-1 TCR/IL-15 NK is an engineered T-Cell Receptor Natural Killer (TCR-NK) cell therapy for advanced synovial sarcoma and myxoid/round cell liposarcoma.
Lead Product(s): NY-ESO-1 TCR/IL-15 NK Cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Recipient: Replay Bio
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 20, 2023
Details:
The collaboration aims for the evaluation of polyamine metabolic inhibitor therapies involving, SBP-101 (ivospemin), in combination with CAR-T cell therapies in preclinical models.
Lead Product(s): Ivospemin,CAR T-cell Therapy
Therapeutic Area: Oncology Product Name: SBP-101
Highest Development Status: PreclinicalProduct Type: Small molecule
Recipient: Panbela Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 13, 2023
Details:
RenovoGem™ (gemcitabine), FDA-approved chemotherapy, delivered via the company’s proprietary delivery system, utilizes pressure-mediated delivery of drug across the arterial wall to bathe tumor tissue in chemotherapy via RenovoTAMP®.
Lead Product(s): Gemcitabine
Therapeutic Area: Oncology Product Name: RenovoGem
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: RenovoRx
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 01, 2023
Details:
The collaboration aims to jointly discover and co-develop protein therapeutics for up to 5 oncology targets in advanced cancers, including small-cell and NSCLC. The agreement combines Generate:Biomedicines’ The Generate Platform with MD Anderson’s clinical research expertise.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Undisclosed
Recipient: Generate Biomedicines
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 27, 2023
Details:
TC BioPharm is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T-lymphocyte product line - Phase 2b/3 pivotal trial for OmnImmune® in treatment of acute myeloid leukemia using the Company's proprietary allogenic CryoTC technology.
Lead Product(s): Gamma Delta T-lymphocyte,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: OmnImmune
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Recipient: TC BioPharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 17, 2023
Details:
Under the agreement, Dr. Andreeff will evaluate the capacity of Eterna’s gene-edited induced pluripotent stem (iPS) cell therapeutic candidates to stimulate enhanced immune responses, including their effects on various aspects of T-cell mediated immunity.
Lead Product(s): iPSC-based Therapeutic
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Recipient: Eterna Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 01, 2022
Details:
VG201 is a first-in-class oncolytic HSV-1 virus that has enhanced oncolytic activity specifically for tumors expressing carcinoembryonic antigen (CEA) and is designed to produce immune-stimulating cytokines IL-12 and IL-15/IL15Rα.
Lead Product(s): VG201
Therapeutic Area: Oncology Product Name: VG201
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Virogin Biotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 08, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
